Skip to content
sellWeak cluster of 310b5-1 plan

Helen Torley sold $4.2M of HALO

PRESIDENT AND CEO at HALOZYME THERAPEUTICS, INC.. 60,000 shares at an average of $69.47, traded Nov 10, 2025, filed Nov 12, 2025.

Warning score
30
Value
$4.2M
60,000 shares
Holdings after
733,719
-8% from before
From 52-week low
+60%
low $42.57, close $68.01
From 52-week high
-13%
high $78.28, as of Nov 10, 2025

Score components

  • Role
    CEO
    +25
  • Trade size
    $4.2M at market
    +25
  • Share of holdings sold
    Sold 8.0% of holdings
    0
  • Cluster
    3 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

HALOOct 9, 2026 · close 110.42
Since filing Nov 12, 2025: +56.3%SPY +15.2% · excess +41.2%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001159036-25-000054, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Nov 10, 2025MOption exercise
Common Stock10b5-1
+20,000$8.11$162k753,719Nov 12, 2025
Nov 10, 2025SOpen-market sale
Common Stock10b5-1
-19,900$68.71$1.4M733,819Nov 12, 2025
Nov 10, 2025SOpen-market sale
Common Stock10b5-1
-100$69.30$6,930733,719Nov 12, 2025
Nov 11, 2025MOption exercise
Common Stock10b5-1
+20,000$8.11$162k753,719Nov 12, 2025
Nov 11, 2025SOpen-market sale
Common Stock10b5-1
-4,500$67.89$306k749,219Nov 12, 2025
Nov 11, 2025SOpen-market sale
Common Stock10b5-1
-4,000$68.80$275k745,219Nov 12, 2025
Nov 11, 2025SOpen-market sale
Common Stock10b5-1
-11,500$69.73$802k733,719Nov 12, 2025
Nov 12, 2025MOption exercise
Common Stock10b5-1
+20,000$8.11$162k753,719Nov 12, 2025
Nov 12, 2025SOpen-market sale
Common Stock10b5-1
-12,718$70.22$893k741,001Nov 12, 2025
Nov 12, 2025SOpen-market sale
Common Stock10b5-1
-6,784$71.09$482k734,217Nov 12, 2025
Nov 12, 2025SOpen-market sale
Common Stock10b5-1
-498$71.67$36k733,719Nov 12, 2025
Nov 10, 2025MOption exercise
Option to Purchase Common Stockderivative10b5-1
-20,000$8.11$162k56,569Nov 12, 2025
Nov 11, 2025MOption exercise
Option to Purchase Common Stockderivative10b5-1
-20,000$8.11$162k36,569Nov 12, 2025
Nov 12, 2025MOption exercise
Option to Purchase Common Stockderivative10b5-1
-20,000$8.11$162k16,569Nov 12, 2025

Related signals

Other insiders at HALOZYME THERAPEUTICS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
23Weak
HALOsell 210b5-1
HALOZYME THERAPEUTICS, INC.
Helen Torley
PRESIDENT AND CEO
$6.6M
60,000 shares
-8%
22Weak
HALOsell 210b5-1
HALOZYME THERAPEUTICS, INC.
Matthew L. Posard
director
$568k
5,230 shares
-9%
33Weak
HALOsell 210b5-1
HALOZYME THERAPEUTICS, INC.
Matthew L. Posard
director
$2.0M
18,996 shares
-24%
23Weak
HALOsell 210b5-1
HALOZYME THERAPEUTICS, INC.
Helen Torley
PRESIDENT AND CEO
$6.4M
60,000 shares
-8%
58Moderate
HALOsell 2
HALOZYME THERAPEUTICS, INC.
Cortney Caudill
SVP, CHIEF OPERATING OFFICER
$2.0M
28,857 shares
-84%
23Weak
HALOsell 210b5-1
HALOZYME THERAPEUTICS, INC.
Helen Torley
PRESIDENT AND CEO
$3.5M
50,000 shares
-6%
15Weak
HALOsell10b5-1
HALOZYME THERAPEUTICS, INC.
Helen Torley
PRESIDENT AND CEO
$3.9M
50,000 shares
-7%
6Weak
HALOsell10b5-1
HALOZYME THERAPEUTICS, INC.
Bernadette Connaughton
director
$141k
2,000 shares
-5%
44Moderate
HALOsell 3
HALOZYME THERAPEUTICS, INC.
Cortney Caudill
SVP, CHIEF OPERATING OFFICER
$278k
4,263 shares
-25%
10Weak
HALOsell 210b5-1
HALOZYME THERAPEUTICS, INC.
Bernadette Connaughton
director
$59k
829 shares
-2%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Helen Torley sold $4.2M of HALO | InsiderTell